Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$7.70−0.23 (-2.90%)

Close on Nov 13, 2026Market cap $77.29MP/E –Yield –

Atara Biotherapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	78.3%	–
Q3 FY2025	Sep 30, 2025	96.7%	–

Parsed from the XBRL in Atara Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Jun 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing